Latest From Biognosys AG
Liquid biopsy is a rapidly developing noninvasive technology for the early detection of cancer. Multiple companies have entered clinical testing, using mostly blood to detect circulating tumor cells and/or circulating tumor DNA. But urine and even cerebral spinal fluid are promising liquids too. Regardless of the fluid, testing costs a fraction of a traditional, invasive tissue biopsy and offers much quicker results.
The potential to use a simple blood test to guide physicians in monitoring cancer therapies, detect early cancers, serve as a companion diagnostic to guide targeted therapeutics and predict the likely course or outcomes of disease in patients has spurred a lot of interest and innovation. Here's a look at emerging companies hoping to make an impact, including insights from interviews conducted with C-Level visitors at the recent Liquid Biopsy Conference in San Francisco. This is the second of a two-part series focusing on the global liquid biopsy market.
Drug Discovery Tools
- Drug Discovery Tools
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Biognosys AG
- Senior Management
Oliver Rinner, PhD, CEO
Lukas Reiter, PhD, CTO
Holger Mueller, PhD, Chief Commercial Officer
- Contact Info
Phone: 44 738 20 40
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.